Robert remains one of the team's prominent litigators, with particular experience of complex patent disputes and advising clients from a range of IP rich industries.
Rob is a partner in the Intellectual Property Group and is based in London.
He has significant experience in both contentious and non-contentious IP work, advising on the full range of issues relating to patents, copyright, trade marks, designs and trade secrets/confidential information.
Rob has particular experience of complex patent disputes, advising clients from a range of IP rich industries, including life sciences, energy and utilities, speciality chemicals, mechanical engineering and electronics on strategic IP issues including lifecycle management.
He was a member of the teams acting for Pfizer in patent cases concerning Viagra and Lipitor, and acted for Synthon in its action against GSK concerning paroxetine mesylate, which resulted in one of the leading House of Lords judgments on the law of novelty in the UK. He also acted for BP Chemicals in two actions against Hoechst Celanese relating to acetic acid production and for Sir Robert McAlpine in a high profile passing off dispute with Alfred McAlpine. More recently he has acted for Synthon in a case relating to the SPC for Memantine and for Rovi Corp in a patent dispute with Virgin Media concerning electronic programme guides. He is currently acting for Allergan in a patent case relating to the use of botulinum toxin products for the treatment of urinary incontinence conditions and for DS Smith PLC in a patent case relating to wheeled pallet products used in the FMCG industry.
Rob obtained a BSc degree in Chemistry and Law, and a BA in Law from Exeter University before undertaking his training with us. He is an associate of the Chartered Institute of Patent Agents (CIPA) and the Institute of Trade Mark Agents (ITMA). He is a frequent lecturer for CIPA and ITMA and currently sits on CIPA’s Exploitation, Competition & General Laws Committee and on the ITMA Review Committee.